Overview
Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.
Description
Single Arm non-controlled study. Patients are prospectively evaluated then treated. Outcomes are tracked after treatment.
Eligibility
Inclusion Criteria:
- Patients will need a diagnosis of Congenital Myasthenic Syndrome by a licensed physician.
- Patients must be able to provide informed consent, or have a guardian who does.
- Patient must be able to travel to the site of treatment.
Exclusion Criteria:
- Patients will be excluded from the trial if they are pregnant or have active cancer (malignancy) at the screening consultation.